INTRODUCTION
Kabuki syndrome (KS) (or Niikawa-Kuroki syndrome, MIM# 147920) is a rare syndrome, characterized by intellectual disability and distinct dysmorphic features, which was originally described by two independent groups in Japan (Kuroki et al., 1981; Niikawa et al., 1981) . The estimated prevalence of KS was estimated at 1:32,000 in the Japanese population. Dominant clinical findings include a characteristic facial appearance, developmental delay and growth retardation and additional features such as hypodontia and persistent fetal fingerpads (Adam and Hudgins, 2005; Matsumoto and Niikawa, 2003) . The unique facial characteristics observed in KS include elongated palpebral fissures and eversion of the lateral one third of the lower eyelid, an arched or nicked eyebrow with sparseness of hairgrowth in the lateral half, relatively large ears with simplified morphology, a depressed nasal tip and a full lower lip. Recently, a gene causing KS was identified through exome sequencing, reporting mutations in the histone methyl transferase (HMT) gene MLL2 in 66% of 53 patients with Kabuki syndrome (Ng et al., 2010) . MLL2 is a member of the so called mixed lineage leukemia (MLL) family of HMT proteins, of which MLL1 (previously called ALL1) has been extensively studied because of it's frequent involvement in chromosomal rearrangements in acute myeloid and/or lymphatic leukemia (Meyer et al., 2006) . MLL2 is the paralog of MLL1, arisen through gene duplication, and is transcribed into a 5,537 amino acid residue protein (NCBI reference sequence NP_003473.3). The MLL protein family is part of the SET domain containing group of HMTs in humans, which is evolutionary homologous to the Drosophila trithorax protein (TRX) (Dillon et al., 2005; Qian and Zhou, 2006) . SET domains are highly conserved in evolution and are the essential catalytic protein subunits that execute the histone lysine methylation which is the core function of HMTs. MLL proteins require complex formation with other proteins, which allows recruitment to target genes and facilitates the catalytic function of the protein's SET domain. MLL proteins add methyl groups specifically to the fourth lysine residue of the lysine side chains of histone H3, referred to as H3K4 methylation which is a transcriptional activation mechanism. Histone methylation in general thus constitutes an evolutionary conserved control mechanism for (epigenetic) gene regulation. Multiple MLL containing protein complexes have been identified in non-redundant constellations despite considerable sequence and functional domain similarities among them (Ansari and Mandal, 2010; Eissenberg and Shilatifard, 2010) . MLL proteins in general are involved in embryogenesis and development most notably through regulation of HOX gene expression and their interaction with nuclear receptors suggests a role in steroid-hormone controlled signaling. MLL2 is involved in regulation of cell adhesion, growth impairment and cell motility (Issaeva et al. 2007 ). Interestingly, methyl transferase pathways in general have been implicated before in the pathology of MR syndromes such as Kleefstra Syndrome (MIM# 610253) which is caused by mutations in the EHMT1 gene, an H3K9 methyl transferase, and Schinzel-Giedion syndrome (MIM#: 269150) which is caused by mutations in the SET1BP1 gene that encodes a protein known to bind to SET domains (Hoischen et al., 2010; Kleefstra, et al., 2009) .
MATERIALS AND METHODS

Patient cohort
The patient cohort consists of 45 index patients (31 female, 14 male) with Kabuki syndrome from the Netherlands (n=38) and Belgium (n=7), diagnosed by pediatricians and clinical geneticists. For the current mutation screen, all patient files were reviewed for inclusion by two clinical experts (CSS, YD) using the guideline:
"Management of Kabuki Syndrome, a Clinical Guideline" published online (http://www.dyscerne.org/dysc/guidelines. In order to assess a potential genotype-phenotype correlation detailed photographic evidence of the KS characteristic facial appearance of the patients was evaluated by two independent clinical experts (JS, MV) without prior knowledge of MLL2 mutation carrier status. A subset of patients have been extensively studied (Schrander-Stumpel, et al., 2005) and all have undergone routine cytogenetic evaluation showing normal karyotypes at the 550-band resolution levels in the past. The majority of the cohort has also been tested on various SNP-microarray and array-CGH platforms which, with the exception of one patient (Table 1 , nr.10) did not result in the identification of any clinically significant de novo CNVs (data not shown) in line with reports by others (Kuniba, et al., 2009) . Patient 10 has been reported before, because of a de novo deletion of exon 5 of the MACROD2 gene, identified by array-CGH (Maas et al., 2007) . Written permission for the studies was obtained from each of the patient's parents or caretakers and the study protocol was approved after evaluation by the local Medical Ethics Committee of the Maastricht University Medical Center (MUMC + ). PCR and sequence analysis DNA was extracted from each proband and their parents (if available) from two independent peripheral blood samples following standard procedures. Mutation screening of the complete coding region of the MLL2 gene was performed by direct sequence analysis in both directions using the ABI Big Dye Terminator Cycle Sequencing Ready Reaction kit and the ABI3730 Genetic Analyzer (Applied Biosystems, Foster City, CA). Primer sets for all 54 exons spanning the MLL2 coding region, including intron-exon boundaries, were either designed by Applied Biosystems (AB) for VariantSEQr SNP discovery or were custom designed. All primers were tagged with M13 extensions to customize further sequence-analysis. All PCR's were performed using a PE9700 thermal cycler. Full details of primer sequences, amplicon lengths and PCR conditions are available on request from the authors. Sequences were aligned with the known MLL2 coding sequence (NCBI reference sequence accession NM_003482.3). Mutation analysis was performed using Mutation Surveyor V3.30 (©SoftGenetics, PA, USA). Mutations identified were confirmed on a DNA sample extracted from the second independent blood sample from the proband if available. The pathogenicity of the mutations was based on a number of genetic criteria: de novo occurence, predicted non-functionality of mutated proteins, location, type and conservation of mutated aminoacids. In silico prediction of functional consequences was performed using Align GVGD (http://agvgd.iarc.fr/agvgd_input.php), SIFT (http://blocks.fhcrc.org/sift/SIFT.html), PolyPhen (http://genetics.bwh.harvard.edu/pph/) and MutationTaster (http://www.mutationtaster.org/). Effects on splicing were investigated in silico using http://www.fruitfly.org/seq_tools/splice.html, http://www.cbs.dtu.dk/services /NetGene2/, http://www.genet. sickkids.on.ca /~ali/splicesitefinder.html and http://rulai.cshl.edu/tools/ESE/). All parents available were tested for the mutations found in their affected child by sequence analysis. Non-paternity was excluded in case of de novo mutations by multiplex VNTR analysis using the AmpFST® Identifiler PCR Amplification kit (Applied Biosystems, Foster City, CA) following the manufacturers protocol.
RESULTS AND DISCUSSION
In total, we detected 34 (75,6%) heterozygous mutations (25 female, 9 male) in 45 index KS patients. The type of mutations as well as their inheritance are presented in Table 1 . In line with the report from Ng et al. (Ng, et al., 2010) , the majority are truncating mutations (nonsense or frameshift mutations), although in our study the number of frameshift mutations was relatively high and the number of nonsense mutations low. In our study we also report the first splice-site mutations (n=4), which adds exon skipping to the spectrum of mechanisms leading to potential abrogation of full-length protein expression. One of the mutations we detected (c.16360C>T (p.Arg5454X), Table 2 ) was also reported in the original study by Ng et al., all others were novel and private. The 34 mutations detected were randomly distributed across the gene with an expected clustering in some of the larger exons (Table 2, Fig.1) . Table 2 presents an overview of the MLL2 mutations detected, together with the mutations reported by Ng et al. In our cohort two patients carry a missense mutation that each result in amino acid changes at the C-terminal end of the protein in highly conserved protein domains (FYRN and SET domains, mutations in green Fig 1. ). As both missense mutations were de novo in nature and the majority of the in silico programs predict these mutations to be pathogenic, it is highly likely that they are causal and affect the function of the protein in a negative way. Additionally, we detected four splice junction mutations affecting the consensus site positions at -1 (patient nr. 26), -2 (patients 7, 27) and +5 (patient 25) , respectively (Table 2, mutation in orange Fig 1) . The first three are predicted to result in exon skipping, of exons 47, 48 and 23, the fourth one (c.13999+5G>A) predicts a profound change, but not necessarily skipping of exon 42. This variant was however also de novo in nature, and therefore we suspect it to be causal. RNA studies will be performed to determine whether exon skipping is the causal mechanism for all these splice-site mutations. 28 out of 34 mutation carriers represent truncating mutations, either nonsense (n=11) or frameshift (n=17). Although merely three of these mutations localize to one of the proteins functional (conserved) domains, functionally all 28 result in the loss of either the entire C-terminal cluster of functional domains (n=26) or significant parts of it (n=2) (Fig.1) . In these cases, truncating mutations abrogate the possibility of complex formation and recruitment and ultimately of methyl transfer onto target lysine residues. As several of the mutations are located within the 50-54 nucleotide perimeter of exon-exon junctions, it is suspected that these will lead to nonsense-mediated decay of mRNA prior to protein synthesis. Table 3 lists the variants and polymorphisms we detected (n=23) in the coding regions and intron-exon boundaries of the MLL2 gene in all patients. Five were located in introns, ten were silent variants and eight were missense variants. Twelve of these variants were detected more than once in the KS population and eleven of these were listed as SNP's. Of the remaining eleven, two were intronic, four were silent and five were missense variants (no listing in the SNP database). The latter five variants were all inherited from an asymptomatic parent, four were identified in patients with an already detected pathogenic mutation and the majority of in silico programs predicts them to be benign. As such, these variants are unlikely to be causative for KS (Table 3) . In a preliminary genotype-phenotype correlation study, we compared key clinical features of KS in patients with an MLL2 mutation to those without an MLL2 mutation in our cohort (Table 4 ). The evaluation of facial characteristics was performed by two independent clinical experts (JS, MV) without prior knowledge of MLL2 mutation carrier status. In our cohort KS patients with a MLL2 mutation were statistically different from patients without a MLL2 mutation with respect to the presence of the unique facial characteristics and growth retardation (threshold -3SD) above the age of 3 years. The other tested characteristics (hypodontia, fingertip pads, hypotonia and hyperlaxity) were equally frequent in both groups. Although larger groups of patients and more elaborate phenotypic characteristics should be evaluated, this study indicates that patients with an MLL2 mutation may represent a clinical subgroup within the KS patient population.
As pointed out by Ng et al. yet other genes might cause KS and could be identified in patients with KS but without a detectable MLL2 mutation. Likewise, MLL2 microdeletions (or microduplications) involving, for example entire exon(s), could still be present in the latter. Although many patients included in this study were assessed previously on various microarray platforms, aberrations at the exon deletion scale could have been missed due to resolution constraints. These patients will be studied by higher resolution microarrays or by semi-quantative PCR based approaches, focusing on the MLL2 region.
The ramifications of MLL2 mutations for early developmental processes, leading to the severe phenotype observed in KS need to be addressed in functional studies following these initial mutation screens. An experimental model such as a mouse Mll2 gene knock-out would provide valuable information but has yet to be developed. Since there is considerable confusion in the literature it needs to be pointed out here that the existing mouse Mll2 knock-out is actually the equivalent of a human MLL4 knock-out due to a recent nomenclature switch that results in mouse Mll2 now being the ortholog of human MLL4 (Glaser et al., 2006) . The emerging spectrum of MLL2 mutations to which this study adds 33 novel mutations further provides insight into Kabuki syndrome's etiology. Specific functional studies can now be designed to understand the disease's underlying mechanisms. As stated above, methyl transferase pathways have been implicated before in the pathology of some intellectual disability syndromes. Given the apparent non-redundancy of HMTs within their respective families and their equally non-redundant modes of gene regulation, a specific pathogenicity for each of the pathways involved make HMTs viable targets for further mutational analyses in the very divergent spectrum of, as of yet, unresolved intellectual disability syndromes.
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